Higher Nodal Yield Tied to Lower Mortality in Oral Cavity Cancer

Share this content:
Higher Nodal Yield Tied to Lower Mortality in Oral Cavity Cancer
Higher Nodal Yield Tied to Lower Mortality in Oral Cavity Cancer

FRIDAY, July 14, 2017 (HealthDay News) -- For clinically node-negative patients with oral cavity squamous cell carcinoma (OCSCC), higher nodal yield (above 24 nodes) is associated with lower mortality, according to a research letter published online July 13 in JAMA Otolaryngology-Head & Neck Surgery.

Chiaojung Jillian Tsai, M.D., Ph.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues examined the survival impact of lymph node count in patients with OCSCC. The National Cancer Database was queried for cN0, M0, OCSCC patients diagnosed from 2004 to 2012. A total of 7,811 patients who received definitive surgery were selected, and overall survival (OS) was assessed from three months after surgery, with a median follow-up of 48.3 months.

The researchers found that OS was 92.2 months and the median node count was 23; 77 percent of patients were pN0. In multivariable analyses, OS was longer for patients with more than 24 nodes versus those who had 24 or fewer nodes (hazard ratio, 0.82). Increased mortality was seen with increased age, comorbidity index, stage, and Medicare or Medicaid insurers. There was a correlation between adjuvant radiation with better OS. Results were similar for 16 and 18 nodes. There was a multivariable adjusted c-index of 0.66.

"In this analysis, higher nodal yield (>24) was associated with lower mortality in cN0 patients with OCSCC receiving definitive surgery," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths